Supplementary Appendix: Final Protocol

For earlier versions of the protocol and a summary of changes during the study, please see the appendix from the original publication

FINAL PROTOCOL

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial

Principal Investigators

Dr. David Palma, MD, MSc, PhD, FRCPC
Radiation Oncologist
OICR Clinician Scientist
London Regional Cancer Program

Prof.dr. Suresh Senan MRCP, FRCR, PhD Professor of Clinical Experimental Radiotherapy Department of Radiation Oncology, VU University Medical Center

London Regional Cancer Program (LRCP) Investigators

Co-Investigators Radiation Oncology

Dr. George Rodrigues, MD, MSc, FRCPC
Dr. Glenn Bauman, MD, FRCPC
Dr. Michael Lock, MD, FRCPC
Dr. Belal Ahmad, MD, FRCPC
Dr. Edward Yu, MD, PhD, FRCPC
Dr. Brian Yaremko, MD, P.Eng., FRCPC

Co-Investigators Radiation Physics

Dr. Stewart Gaede, PhD Dr. Jeff Chen, PhD

Co-Investigator Medical Oncology

Dr. Eric Winquist, MD, FRCPC

Biostatistician


Mr. Larry Stitt, MSc

VU University Amsterdam (VUmc) Investigators

Co-Investigators Radiation Oncology

Dr. Niels Haasbeek, MD, PhD

STEREOTACTIC ABLATIVE RADIOTHERAPY FOR COMPREHENSIVE TREATMENT OF OLIGOMETASTATIC TUMORS (SABR-COMET): A RANDOMIZED PHASE II TRIAL



Primary Endpoint

- Overall Survival
 - o Defined as time from randomization to death from any cause

Secondary endpoints:

- Quality of life
 - Assessed with the Functional Assessment of Cancer Therapy: General (FACT-G)
- Toxicity
 - Assessed by the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4 for each organ treated (e.g. liver, lung, bone)]
- Progression-free survival
 - o Time from randomization to disease progression at any site or death
- Lesional control rate
- Number of cycles of further chemotherapy/systemic therapy

Required Sample Size: 99 Patients

INDEX

- 1.0 Introduction
- 2.0 Objectives
- 3.0 Trial Design
- 4.0 Study Population
- 5.0 Pre-Treatment Evaluation
- 6.0 Treatment Plan
- 7.0 Adverse Events
- 8.0 Subject Withdrawal
- 9.0 Follow-up Evaluation and Assessment of Efficacy
- 10.0 Statistical Considerations and Sample Size Calculation
- 11.0 Ethical Considerations
- 12.0 Authorship
- 13.0 Financial Support

<u>APPENDICES</u>

- 1. Eligibility Checklist
- 2. Follow-up schedule
- 3. Letter of Consent
- 4. Quality of Life Questionnaire
- 5. Common Toxicity Criteria

1.0 INTRODUCTION AND RATIONALE

1.1 Background

The oligometastatic disease state was first defined in 1995 and refers to an stage of disease where cancer has spread beyond the site of origin, but is not yet widely metastatic. In such a state of limited metastatic disease burden, it is hypothesized that eradication of all sites of metastatic disease could result in long-term survival, or even cure, in some patients. Ablation of metastatic deposits can be achieved surgically, or through stereotactic ablative radiotherapy (SABR), a new radiotherapy technology that delivers very large, hypofractionated doses of radiotherapy to small tumor targets, with high rates of local control.

Clinical evidence to support the presence of an oligometastatic state is emerging in both the surgical and SABR literature: in a study of over 5200 patients with lung metastases who underwent surgical resection, a 5-year survival of 36% was reported in patients who achieved a complete resection, much higher than would be expected for stage IV disease.³ Similarly, in patients treated with SABR for 1-3 lung metastases from a variety of primary tumors, local control with SABR was 96% at 2-years, and 2-year survival was 39%.⁴ Long-term survival has been demonstrated in patients treated for oligometastases with surgery or SABR at several other tumor sites, including liver, brain, bone, and adrenal metastases.^{2,5-8} However, even after such treatment, the risk of further metastases after ablative treatment is high, up to 60-80% in some studies.^{4,5} In some cases, SABR can be used for further salvage at newly progressive sites.⁹

1.2 Rationale

Despite the apparent achievement of long-term survival with ablative treatment for oligometastatic disease, the level of evidence to support such treatments is weak in many cases, often based on single-arm studies without appropriate controls. Patients included in such reports are highly selected, based on good performance status and slow pace of tumor progression. It has been suggested that the long-term survival achieved with treatment of oligometastases is a result of the selection of fit patients with very slow-growing tumors, rather than the result of treatment intervention. ¹¹

Randomized trials are therefore necessary to establish the utility of ablative treatment of oligometastatic disease, ^{10,12}, but such randomized trials are rare. One such trial, Radiation Therapy and Oncology Group Trial 9508, compared whole brain radiotherapy (WBRT) with WBRT + stereotactic treatment for patients with 1-3 brain metastases, and found a OS advantage only in patients with a single metastasis and those patients in most favorable baseline recursive partitioning analysis (RPA) prognostic group. ¹³ Patients with inferior baseline prognostic factors did not achieve a survival benefit from stereotactic treatment. In 2010, the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) trial was launched, comparing metastatectomy with best supportive care in patients with pulmonary metastases from colorectal cancer. ¹⁴

In summary, it is unclear if all patients with oligometastatic disease benefit from SABR, in terms of improved survival or improved quality of life. Although SABR generally results in ablation of each metastatic target, patients remain at high risk of further metastatic progression. Results from SABR for treatment of oligometastases in published studies appears promising, but these promising results may be due to patient selection, rather than treatment intervention, and are based on comparisons with historical controls. The benefit of comprehensive treatment of oligometastases can only be demonstrated conclusively in the context of a randomized trial.

2.0 OBJECTIVES

To assess the impact of a comprehensive oligometastatic SABR treatment program on overall survival and quality of life in patients with up to 5 metastatic cancer lesions, compared to patients who receive standard of care treatment alone.

Primary Endpoint

- Overall Survival
 - Defined as time from randomization to death from any cause

Secondary endpoints:


- Quality of life
 - Assessed with the Functional Assessment of Cancer Therapy: General (FACT-G)
- Toxicity
 - Assessed by the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4 for each organ treated (e.g. liver, lung, bone)]
- Progression-free survival
 - o Time from randomization to disease progression at any site or death
- Lesional control rate
- Number of cycles of further chemotherapy/systemic therapy

3.0 STUDY DESIGN

This study is designed as a randomized phase II screening study. Patients will be randomized between current standard of care treatment (Arm 1) vs. standard of care treatment + SABR (Arm 2) to sites of known disease. Patients will be randomized in a 1:2 ratio to Arm 1 vs. Arm 2, respectively.

The randomized phase II design is required for 3 reasons:

- 1. The randomization will provide an appropriate control group to serve as a comparator for the experimental arm. Historical or contemporaneous non-randomized controls would not be appropriate due to the multitude of biases that could be introduced by patient selection and other confounders.
- 2. A small sample size will allow for adequate power to assess for an early overall survival difference, quality of life, and to evaluate toxicity in the SABR arm.
- 3. The results will allow for a decision as to whether a multi-institutional phase III trial is warranted, and inform the design of such a trial.



4.0 PATIENT SELECTION

4.1 Inclusion Criteria

- Age 18 or older
- Willing to provide informed consent
- Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.
- ECOG performance status 0-1
- Controlled primary tumor
 - defined as: at least 3 months since original tumor treated definitively, with no progression at primary site
- All sites of disease can be safely treated based on criteria below
- Maximum size of 3 cm for brain lesions
- Maximum size of 5 cm for lesions outside the brain, except:
 - Bone metastases up to 6 cm may be included, if in the opinion of the local PI it can be treated safely (e.g. rib, scapula, pelvis)

•

- Maximum 3 metastases in any single organ system (i.e. lung, liver, brain, bone), and the total number of metastases must be 5 or less. For example, a patient with two liver metastases and two lung metastases is eligible.
- Life expectancy >6 months
- Not a candidate for surgical resection at all sites: surgery to all sites not recommended by multidisciplinary team, or unfit or declining surgery
- Prior chemotherapy allowed but no chemotherapy (cytotoxic or molecularly targeted agents) therapy 4 weeks prior to first fraction of radiotherapy, during radiotherapy, or for two weeks after last fraction. Hormonal therapy is allowed.
- Patients with metastases that have been previously treated (e.g. prior resection, RFA or radiotherapy):
 - o If that previously treated metastasis is controlled on imaging, the patient is eligible for this study and that site does not need treatment
 - o If that previously treated metastasis is NOT controlled on imaging:
 - If the previous treatment was surgery, the patient is eligible if that site can be treated by SABR
 - If the previous treatment was radiotherapy or RFA, the patient is ineligible.
- Patient presented at multidisciplinary tumor board or quality-assurance rounds prior to randomization, with consensus opinion that entry into the study is appropriate.

4.2 Exclusion Criteria

- Serious medical comorbidities precluding radiotherapy
- Bone metastasis in a femoral bone
- Patients with 1-3 brain metastasis and no disease elsewhere (these patients should not be randomized but treated with stereotactic radiotherapy as per results of randomized trials)
- Prior radiotherapy to a site requiring treatment
- Complete response to first-line chemotherapy (i.e. no measurable target for SABR)
- Malignant pleural effusion
- Inability to treat all sites of active disease
- Clinical or radiologic evidence of spinal cord compression OR tumor within 3 mm of spinal cord on MRI.
- Dominant brain metastasis requiring surgical decompression
- Pregnant or lactating women

5.0 PRE-TREATMENT EVALUATION

Required:

- History and Physical Examination
 - Including prior cancer therapies and concomitant medications

 \cap

- Standard of care restaging within 12 weeks prior to randomization:
 - o Brain CT or MRI imaging (for tumor sites with propensity for brain metastasis)
 - o Body imaging:
 - CT neck/chest/abdomen/pelvis with bone scan required
 - PET-CT is only required for specific evidence-based indications, as defined by the Ontario Health Insurance Program, and in such cases the CT neck/chest/abdomen/pelvis and bone scan are not required:
 - Solitary pulmonary nodules for which a needle biopsy is unsuccessful or not possible
 - Colorectal cancer with a rising CEA but equivocal imaging otherwise
 - For other indications, at the discretion of the treating oncologists, PET scans may be done but are not required. For Ontario sites, these can be accessed through the Ontario PET registry or PET Access program.
 - MRI spine for patients with vertebral or paraspinal metastases
 - Liver function tests (AST,ALT,GGT, alkaline phosphatase) for patients with liver metastases
 - o Pregnancy test for women of child-bearing age
- Histologically confirmation of malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.
- Informed consent required

5.1 Randomization

The study will employ a 1:2 randomization between Arm 1:Arm 2 (Figure 1). The sample size allows for one stratification factor at randomization: number of metastatic sites (1-3 vs. 4-5). Randomization will occur in permuted blocks of nine.

6.0 TREATMENT PLAN

6.0.1 Standard Arm (Arm 1)

Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Patients in this arm should not receive stereotactic doses or radiotherapy boosts.

Treatment recommendations are as follows:

Brain: Whole brain radiotherapy

i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions

Lung: Palliative radiotherapy as per 2011 consensus guidelines. 15

i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions

Bone: Palliative radiotherapy as per 2011 consensus guidelines.¹⁶

i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions

Liver: 20 Gy in 5 fractions if standard institutional practice

6.0.2 Treatment Planning for Standard Arm

Treatment planning is to be done using CT simulation or conventional simulation (fluoroscopy) as per individual institutional practice. Simple beam arrangements, such as parallel opposed beams, are favored wherever possible.

6.1 Experimental Arm (Arm 2)

All treatments in this study are based on current protocols in clinical use at the LRCP and VUmc for treatment of lung,¹⁷ liver,¹⁸ brain,^{19,20} and spinal cord²¹ metastases. The guiding principle for radiotherapy is to achieve disease control but to minimize any potential adverse impact on quality of life. Concurrent chemotherapy or targeted therapy at the time of radiotherapy is not permitted within the 4 weeks prior to SABR. Hormone therapy is permitted.

6.1.1 Dose/Fractionation

Doses and fractionations by tumor site are shown in Table 1.

6.1.2 Immobilization

Treatment will be setup using reproducible positioning, verified using an on-line protocol, for all patients in this study. Immobilization may include a custom immobilization device, such as thermoplastic shell or vac-lok bag, as per individual institutional practice when delivering SABR. Some centers do not use immobilization devices and have demonstrated high degrees of accuracy; this is acceptable in this study.

6.1.3 Imaging/Localization/Registration

All patients in Arm 2 will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. Axial CT images will be obtained throughout the region of interest. For centres using stereotactic radiosurgery platforms, real-time tumor tracking and orthogonal imaging systems are permitted.

Table 1. Dose and fractionations by site

Any center which is not yet experienced in lesions at any specific sub-site (e.g. adrenal metastases) shall be eligible to participate by including only patients with lesions at other pre-specified sites

It is strongly recommended that the doses to organs at risk are not to be exceeded – in some specific cases, this may require lower doses or higher fractionations than listed here. Such changes in dose will require approval of one of the local principal investigators. (see section 6.2)

Tumor Location	Description	Total Dose (Gy)	Number of fractions	Dose per fraction (Gy)	Frequency
Lung	Tumors 3 cm or less surrounded by lung parenchyma	54	3	18	Every second day
	Abutting chest wall or >3 cm	55	5	11	Every second day
	Within 2 cm of mediastinum or brachial plexus	60	8*	7.5	Every second day
Bone	Any bone except femur	35 Gy	5	7	Daily
	Vertebral body: additional options	16-20 Gy <i>OR</i>	1	16-20	Single dose Every second
		30 Gy	3	10	day
Brain Metastases	Non-radiosurgical (If whole brain	40 Gy to metastases	5	8 Gy to lesion	Daily
	treated, then simultaneous boost to each lesion)	20 Gy whole brain (optional)	5	4 Gy WBRT	Daily
	Radiosurgical ≤1 cm >1 and ≤2 cm >2 and ≤3 cm Optional whole brain to follow (see text)	22-24 Gy 20-22 Gy 18-20 Gy	1 1 1	22-24 Gy 20-22 Gy 18-20 Gy	Single dose Single dose Single dose
Liver	LRCP site: Dose is based on calculated normal tissue probability of <5%				Every second day
	Other sites	45-60	3-8	7.5-15	Every second day
Adrenal		60 Gy	8	7.5	Every second day

^{*}If esophageal dose constraints cannot be met, 12 fractions should be used.

For centres using stereotactic radiosurgery platforms, single-fraction CNS doses will be permitted. Recommend doses are 22-24 Gy in 1 fraction for lesions up to 1cm, 20-22 Gy for lesions >1 cm up to 2 cm, and 18-20 Gy in 1 fraction for lesions >2 cm up to 3 cm. If delivered, whole brain radiotherapy doses may be 20 Gy in 5 fractions or 30 Gy in 10 fractions, and should be delivered *after* SRS to avoid a situation where a lesion resolves after WBRT and does not receive an ablative dose.

6.1.3.1 4D-CT scanning

Physics will review the 4D-CT images and will perform the following quality assurance procedures indicated on the 4D-CT template designed specifically for SABR:

- i) Ensure all end inspiration (0%) tags exist and are in the right place. This ensures image integrity.
- ii) If the quality of the 4D-CT images are not sufficient (determined by Physics), then standard 3D-CRT will be performed on the fast helical CT or Untagged Average CT.
- iii) Motion measurements in all 3 directions are performed:
 - 1) If the motion is less than or equal to 7 mm and the good quality images exist, then treatment planning may be performed on the Untagged Average CT with the 50% or 60% phase (End Expiration) and the 0% phase being fused to it. This will define the IGTV.
 - 2) If the motion is greater than 7 mm in any one direction, then respiratory-gated radiotherapy will be considered. In this case, treatment planning will be performed on a subset average CT dataset (usually labeled either 30%-60% Avg CT or 40%-70% Avg CT) generated by Physics. This is an average CT over the intended gated interval. Therefore, the GTV that is delineated on this scan will incorporate residual motion in the intended gated interval. The 0% phase will also be fused to this dataset. The PTV for planning will include the GTV delineated on the subset average CT plus margins for microscopic extension (Physician's discretion) and setup uncertainty. The GTV_0% should also be delineated and combined with the GTV delineated on the subset average CT to define an additional volume labeled IGTV_CBCT. This contour may be used for image registration with CBCT only.

6.1.4 Volume Definitions (Arm 2)

For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. No additional margin will be added for microscopic spread of disease, consistent with current protocols (i.e. Clinical Target Volume [CTV]=GTV). For vertebral lesions, the entire vertebral body may be considered the CTV, as per institutional practice. A Planning Target Volume (PTV) margin of 2-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy: 2 mm margins may be used for spinal stereotactic treatments, 2 mm for brain tumors, and 5 mm for other sites. For whole brain radiotherapy with a simultaneous boost to metastatic deposit, a PTV margin is not required for each metastatic deposit, and a PTV margin (~ 2 mm) will be added to the whole brain. Organs at risk visible in the planning CT scan (Table 2-5) will be contoured. For radiosurgery platforms, a PTV margin of 0-1 mm is permitted.

For spinal lesions, a pre-treatment MRI is required to assess the extent of disease and position of the cord. This must be fused with the planning CT scan. A Planning Organ at Risk Volume (PRV) expansion of 2 mm will be added to the spinal cord, and dose constraints for the spinal cord apply to this PRV. For radiosurgery platforms, a PRV margin of 1 mm is permitted for the spinal cord.

Table 2. Normal tissue dose constraints for 1-3 fractions SABR regimens. From Timmerman $\it et al. (2008^{22})$

Serial Tissue	Volume (mL) \	/olume Max (Gy)	Max Point Dose (Gy)	Endpoint (≥Grade 3)
	SINGLE-F	RACTION TREAT	MENT	
Optic pathway	< 0.2	8	10	Neuritis
Cochlea			12	Hearing loss
Brainstem	<1	10	15	Cranial neuropathy
Spinal cord	< 0.25	10	14	Myelitis
	< 1.2	7		
Cauda equina	<5	14	16	Neuritis
Sacral plexus	<3	14.4	16	Neuropathy
Esophagus*	<5	14.5	19	Stenosis/fistula
lpsilateral brachial plexus	<3	14.4	16	Neuropathy
Heart/pericardium	< 15	16	22	Pericarditis
Great vessels	< 10	31	37	Aneurysm
Trachea and ipsilateral bronchus*	<4	8.8	22	Stenosis/fistula
Skin	< 10	14.4	16	Ulceration
Stomach	< 10	13	16	Ulceration/fistula
Duodenum*	<5	8.8	16	Ulceration
Jejunum/ileum*	<5	9.8	19	Enteritis/obstruction
Colon*	<20	11	22	Colitis/fistula
Rectum* Bladder wall	<20	11	22 22	Proctitis/fistula
Penile bulb	<15 <3	8.7 14	34	Cystitis/fistula
Femoral heads (right and left)	<10	14	34	Impotence Necrosis
Renal hilum/vascular trunk	< 2/3 volume	10.6		Malignant hypertension
			D M (O.)	· ,.
	ical Volume (ml	D Critical Vol	ume Dose Max (Gy)	Endpoint (≥Grade 3
Lung (right and left)	1,500		7	Basic lung function
Lung (right and left)	1,000		7.4	Pneumonitis
Liver	700		9.1	Basic liver function
Renal cortex (right and left)	200		8.4	Basic renal function
Serial Tissue	Volume (mL) \	/olume Max (Gy)	Max Point Dose (Gy)	Endpoint (≥Grade 3)
	THREE-FI	RACTION TREAT	MENT	
Optic pathway	< 0.2	15 (5 Gy/fx)	19.5 (6.5 Gy/fx)	Neuritis
Cochlea			20 (6.67 Gy/fx)	Hearing loss
Brainstem	<1	18 (6 Gy/fx)	23 (7.67 Gy/fx)	Cranial neuropathy
Spinal cord	< 0.25	18 (6 Gy/fx)	22 (7.33 Gy/fx)	Myelitis
	<1.2	11.1 (3.7 Gy/fx)		
Cauda equina	<5	21.9 (7.3 Gy/fx)	24 (8 Gy/fx)	Neuritis
Sacral plexus	<3	22.5 (7.5 Gy/fx)	24 (8 Gy/fx)	Neuropathy
Esophagus*	<5	21 (7 Gy/fx)	27 (9 Gy/fx)	Stenosis/fistula
Ipsilateral brachial plexus	<3	22.5 (7.5 Gy/fx)	24 (8 Gy/fx)	Neuropathy
Heart/pericardium	< 15	24 (8 Gy/fx)	30 (10 Gy/fx)	Pericarditis
Great vessels	< 10			Aneurysm
		39 (13 Gy/fx)	45 (15 Gy/fx)	,
Trachea and ipsilateral bronchus*	<4	15 (5 Gy/fx)	30 (10 Gy/fx)	Stenosis/fistula
Skin	<4 <10	15 (5 Gy/fx) 22.5 (7.5 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx)	Stenosis/fistula Ulceration
Skin Stomach	<4 <10 <10	15 (5 Gy/fx) 22.5 (7.5 Gy/fx) 21 (7 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx)	Stenosis/fistula Ulceration Ulceration/fistula
Skin Stomach Duodenum*	<4 <10 <10 <5	15 (5 Gy/fx) 22.5 (7.5 Gy/fx) 21 (7 Gy/fx) 15 (5 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx)	Stenosis/fistula Ulceration Ulceration/fistula Ulceration
Skin Stomach Duodenum* Jejunum/ileum*	<4 <10 <10 <5 <5	15 (5 Gy/fx) 22.5 (7.5 Gy/fx) 21 (7 Gy/fx) 15 (5 Gy/fx) 16.2 (5.4 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 27 (9 Gy/fx)	Stenosis/fistula Ulceration Ulceration/fistula Ulceration Enteritis/obstruction
Skin Stomach Duodenum* Jejunum/ileum* Colon*	<4 <10 <10 <5 <5 <20	15 (5 Gy/fx) 22.5 (7.5 Gy/fx) 21 (7 Gy/fx) 15 (5 Gy/fx) 16.2 (5.4 Gy/fx) 20.4 (6.8 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 27 (9 Gy/fx) 30 (10 Gy/fx)	Stenosis/fistula Ulceration Ulceration/fistula Ulceration Enteritis/obstruction Colitis/fistula
Skin Stomach Duodenum* Jejunum/ileum* Colon* Rectum*	<4 <10 <10 <5 <5 <20 <20	15 (5 Gy/fx) 22.5 (7.5 Gy/fx) 21 (7 Gy/fx) 15 (5 Gy/fx) 16.2 (5.4 Gy/fx) 20.4 (6.8 Gy/fx) 20.4 (6.8 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 27 (9 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx)	Stenosis/fistula Ulceration Ulceration/fistula Ulceration Enteritis/obstruction Colitis/fistula Proctitis/fistula
Skin Stomach Duodenum* Jejunum/ileum* Colon* Rectum* Bladder wall	<4 <10 <10 <5 <5 <20 <20 <15	15 (5 Gy/fx) 22.5 (7.5 Gy/fx) 21 (7 Gy/fx) 15 (5 Gy/fx) 16.2 (5.4 Gy/fx) 20.4 (6.8 Gy/fx) 20.4 (6.8 Gy/fx) 15 (5 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 27 (9 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx)	Stenosis/fistula Ulceration Ulceration/fistula Ulceration Enteritis/obstruction Colitis/fistula Proctitis/fistula Cystitis/fistula
Skin Stomach Duodenum* Jejunum/ileum* Colon* Rectum* Bladder wall Penile bulb	<4 <10 <10 <5 <5 <20 <20 <15 <3	15 (5 Gy/fx) 22.5 (7.5 Gy/fx) 21 (7 Gy/fx) 15 (5 Gy/fx) 16.2 (5.4 Gy/fx) 20.4 (6.8 Gy/fx) 20.4 (6.8 Gy/fx) 15 (5 Gy/fx) 21.9 (7.3 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 27 (9 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx)	Stenosis/fistula Ulceration Ulceration/fistula Ulceration Enteritis/obstruction Colitis/fistula Proctitis/fistula Cystitis/fistula Impotence
Skin Stomach Duodenum* Jejunum/ileum* Colon* Rectum* Bladder wall Penile bulb Femoral heads (right and left)	<4 <10 <10 <5 <5 <20 <20 <15 <3 <10	15 (5 Gy/fx) 22.5 (7.5 Gy/fx) 21 (7 Gy/fx) 15 (5 Gy/fx) 16.2 (5.4 Gy/fx) 20.4 (6.8 Gy/fx) 20.4 (6.8 Gy/fx) 15 (5 Gy/fx) 21.9 (7.3 Gy/fx) 21.9 (7.3 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 27 (9 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx)	Stenosis/fistula Ulceration Ulceration/fistula Ulceration Enteritis/obstruction Colitis/fistula Proctitis/fistula Cystitis/fistula Impotence Necrosis
Skin Stomach Duodenum* Jejunum/ileum* Colon* Rectum* Bladder wall Penile bulb Femoral heads (right and left) Renal hilum/vascular trunk	<4 <10 <10 <5 <5 <20 <20 <15 <3 <10 <2/3 volume	15 (5 Gy/fx) 22.5 (7.5 Gy/fx) 21 (7 Gy/fx) 15 (5 Gy/fx) 16.2 (5.4 Gy/fx) 20.4 (6.8 Gy/fx) 20.4 (6.8 Gy/fx) 15 (5 Gy/fx) 21.9 (7.3 Gy/fx) 21.9 (7.3 Gy/fx) 18.6 (6.2 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 27 (9 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx) 42 (14 Gy/fx)	Stenosis/fistula Ulceration Ulceration/fistula Ulceration Enteritis/obstruction Colitis/fistula Proctitis/fistula Cystitis/fistula Impotence Necrosis Malignant hypertension
Skin Stomach Duodenum* Jejunum/ileum* Colon* Rectum* Bladder wall Penile bulb Femoral heads (right and left) Renal hilum/vascular trunk Parallel Tissue Crit	<4 <10 <10 <5 <5 <20 <20 <15 <3 <10 <2/3 volume	15 (5 Gy/fx) 22.5 (7.5 Gy/fx) 21 (7 Gy/fx) 15 (5 Gy/fx) 16.2 (5.4 Gy/fx) 20.4 (6.8 Gy/fx) 20.4 (6.8 Gy/fx) 15 (5 Gy/fx) 21.9 (7.3 Gy/fx) 21.9 (7.3 Gy/fx) 18.6 (6.2 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 27 (9 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx) 42 (14 Gy/fx)	Stenosis/fistula Ulceration Ulceration/fistula Ulceration Enteritis/obstruction Colitis/fistula Proctitis/fistula Cystitis/fistula Impotence Necrosis Malignant hypertension Endpoint (≥Grade 3
Skin Stomach Duodenum* Jejunum/ileum* Colon* Rectum* Bladder wall Penile bulb Femoral heads (right and left) Renal hilum/vascular trunk Parallel Tissue Crit Lung (right and left)	<4 <10 <10 <5 <5 <20 <20 <15 <3 <10 <2/3 volume (ml	15 (5 Gy/fx) 22.5 (7.5 Gy/fx) 21 (7 Gy/fx) 15 (5 Gy/fx) 16.2 (5.4 Gy/fx) 20.4 (6.8 Gy/fx) 20.4 (6.8 Gy/fx) 15 (5 Gy/fx) 21.9 (7.3 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 27 (9 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx) 42 (14 Gy/fx) 42 (14 Gy/fx)	Stenosis/fistula Ulceration Ulceration/fistula Ulceration Enteritis/obstruction Colitis/fistula Proctitis/fistula Cystitis/fistula Impotence Necrosis Malignant hypertension Endpoint (≥Grade 3 Basic lung function
Skin Stomach Duodenum* Jejunum/ileum* Colon* Rectum* Bladder wall Penile bulb Femoral heads (right and left) Renal hilum/vascular trunk Parallel Tissue Crit Lung (right and left) Lung (right and left)	<4 <10 <10 <5 <5 <20 <20 <15 <3 <10 <2/3 volume 1,500 1,000	15 (5 Gy/fx) 22.5 (7.5 Gy/fx) 21 (7 Gy/fx) 15 (5 Gy/fx) 16.2 (5.4 Gy/fx) 20.4 (6.8 Gy/fx) 20.4 (6.8 Gy/fx) 15 (5 Gy/fx) 21.9 (7.3 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 27 (9 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx) 42 (14 Gy/fx) 42 (14 Gy/fx) ume Dose Max (Gy) 5 (3.5 Gy/fx) 4 (3.8 Gy/fx)	Stenosis/fistula Ulceration Ulceration/fistula Ulceration Enteritis/obstruction Colitis/fistula Proctitis/fistula Cystitis/fistula Impotence Necrosis Malignant hypertension Endpoint (≥Grade 3) Basic lung function Pneumonitis
Skin Stomach Duodenum* Jejunum/ileum* Colon* Rectum* Bladder wall Penile bulb Femoral heads (right and left) Renal hilum/vascular trunk Parallel Tissue Crit Lung (right and left)	<4 <10 <10 <5 <5 <20 <20 <15 <3 <10 <2/3 volume (ml	15 (5 Gy/fx) 22.5 (7.5 Gy/fx) 21 (7 Gy/fx) 15 (5 Gy/fx) 16.2 (5.4 Gy/fx) 20.4 (6.8 Gy/fx) 20.4 (6.8 Gy/fx) 15 (5 Gy/fx) 21.9 (7.3 Gy/fx)	30 (10 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 24 (8 Gy/fx) 27 (9 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx) 30 (10 Gy/fx) 42 (14 Gy/fx) 42 (14 Gy/fx)	Stenosis/fistula Ulceration Ulceration/fistula Ulceration Enteritis/obstruction Colitis/fistula Proctitis/fistula Cystitis/fistula Impotence Necrosis Malignant hypertension Endpoint (≥Grade 3) Basic lung function

Table 3. Normal tissue dose constraints for **FIVE**-fraction SABR regimens. From Timmerman $\it et al.$, 2008 22

Serial Tissue	Volume (mL)	Volume Max (Gy)	Max Point Dose (Gy)	Endpoint (≥Grade 3)			
FIVE-FRACTION TREATMENT							
Optic pathway	< 0.2	20 (4 Gy/fx)	25 (5 Gy/fx)	Neuritis			
Cochlea			27.5 (5.5 Gy/fx)	Hearing loss			
Brainstem	<1	26 (5.2 Gy/fx)	31 (6.2 Gy/fx)	Cranial neuropathy			
Spinal cord	< 0.25	22.5 (4.5 Gy/fx)	30 (6 Gy/fx)	Myelitis			
•	<1.2	13.5 (2.7 Gy/fx)	-	-			
Cauda equina	<5	30 (6 Gy/fx)	34 (6.4 Gy/fx)	Neuritis			
Sacral plexus	<3	30 (6 Gy/fx)	32 (6.4 Gy/fx)	Neuropathy			
Esophagus*	< 5	27.5 (5.5 Gy/fx)	35 (7 Gy/fx)	Stenosis/fistula			
lpsilateral brachial plexus	<3	30 (6 Gy/fx)	32 (6.4 Gy/fx)	Neuropathy			
Heart/pericardium	< 15	32 (6.4 Gy/fx)	38 (7.6 Gy/fx)	Pericarditis			
Great vessels	< 10	47 (9.4 Gy/fx)	53 (10.6 Gy/fx)	Aneurysm			
Trachea and ipsilateral bronchus*	<4	18 (3.6 Gy/fx)	38 (7.6 Gy/fx)	Stenosis/fistula			
Skin	< 10	30 (6 Gy/fx)	32 (6.4 Gy/fx)	Ulceration			
Stomach	< 10	28 (5.6 Gy/fx)	32 (6.4 Gy/fx)	Ulceration/fistula			
Duodenum*	<5	18 (3.6 Gy/fx)	32 (6.4 Gy/fx)	Ulceration			
Jejunum/ileum*	<5	19.5 (3.9 Gy/fx)	35 (7 Gy/fx)	enteritis/obstruction			
Colon*	<20	25 (5 Gy/fx)	38 (7.6 Gy/fx)	colitis/fistula			
Rectum*	< 20	25 (5 Gy/fx)	38 (7.6 Gy/fx)	proctitis/fistula			
Bladder wall	< 15	18.3 (3.65 Gy/fx)	38 (7.6 Gy/fx)	cystitis/fistula			
Penile bulb	<3	30 (6 Gy/fx)	50 (10 Gy/fx)	Impotence			
Femoral heads (right and left)	< 10	30 (6 Gy/fx)	-	Necrosis			
Renal hilum/vascular trunk	<2/3 volume	23 (4.6 Gy/fx)		Malignant hypertension			
Parallel Tissue Crit	ical Volume (n	nL) Critical Volu	ıme Dose Max (Gy)	Endpoint (≥Grade 3)			
Lung (right and left)	1,500	12.5	5 (2.5 Gy/fx)	Basic lung function			
ung (right and left)	1000		5 (2.7 Gy/fx)	Pneumonitis			
iver	700	2	1 (4.2 Gy/fx)	Basic liver function			
Renal cortex (right and left)	200	17.9	5 (3.5 Gy/fx)	Basic renal function			

^{*}Avoid circumferential irradiation.

Table 4. Additional normal tissue dose constraints for **EIGHT**-fraction SABR regimens. Dose conformality requirements from Table 5 also apply for lung lesions. Note: for targets overlapping the stomach or esophagus, 12 fractions should be used, with a maximum dose of 48 Gy in 12 fractions for either organ. For any organs not listed, or for OARs for 12 fraction regimens, a biologically effective dose can be calculated using an alpha-beta ratio of 2.

<u>Structure</u>	Maximum Dose
Liver	At least 700 cc below 22 Gy (unless using
	NTCP calculation method)
Kidney (right and left)	At least 200 cc below 21 Gy
Spinal Cord	32 Gy point dose
	V(27 Gy) < 0.25 cc
	V(16 Gy) < 1.25 cc
Stomach	40 Gy point dose
	V(34 Gy) < 10 cc
Esophagus	40 Gy point dose
	V(33 Gy) < 5 cc
Great Vessels	65 Gy point dose
	V(58 Gy) < 10 cc
Trachea and Ipsilateral Mainstem	40 Gy point dose
Bronchus	V(21.5 Gy) < 4 cc
Ipsilateral Brachial Plexus	39 Gy point dose
	V(36.5 Gy) < 3 cc
Heart/Pericardium	46 Gy point dose
	V(39 Gy) < 15 cc
Duodenum	39 Gy point dose
	V(21.5 Gy) < 5 cc
Jejunum/lleum	40 Gy point dose
	V(23 Gy) < 5 cc

V(X) Gy): volume of structure receiving X Gy or more (i.e. for the stomach, V34 Gy is the volume of stomach receiving 34 Gy or more).

Table 5. Dose conformality parameters for lung SABR treatments From Hurkmans *et al*, 2010¹⁷

Radiation Oncology 2009, 4:1

http://www.ro-journal.com/content/4/1/1

Table 1: Dose conformity requirements and definition of protocol deviations. $R_{100\%}$ and $R_{50\%}$ = ratio of respectively the 100% and 50% Prescription Isodose Volume to the PTV. $D_{2 \text{ cm}}$ = dose maximum at 2 cm from the PTV as percentage of the prescribed dose. $V_{20 \text{ Gy}}$ = Percent of lung receiving 20 Gy or more (both lungs minus GTV).

			lgorithms)	dels (standard a	Type A mo			
PTV (d	_y (%)	V _{20 G}	m (%)		50%	R	R _{100%}	
	ation	Devia	ation	Devi	iation	Dev	eviation	D
	Minor	None	Minor	None	Minor	None	Minor	None
0-20	4-6	<4	55–60	<55	8–10	<8	1.15–1.25	<1.15
20-4	6–8	<6	65-70	<65	7–8	<7	1.15-1.25	<1.15
>40	8–10	<8	65–75	<65	6–6.5	<6	1.10-1.20	<1.10
			ed algorithms)	(more advance	Type B models			
PTV (d	_y (%)	V _{20 G}	m (%)	D _{2 c}	50%	R	R _{100%}	
	ation	Devia	ation	Devi	iation	Dev	eviation	D
	Minor	None	Minor	None	Minor	None	Minor	None
0–20	5–8	<5	65–75	<65	12–14	<12	1.25–1.40	<1.25
20-4	6-10	<6	70-80	<70	9–11	<9	1.15-1.25	<1.15
>40	10–15	<10	70-80	<70	6–8	<6	1.10-1.20	<1.10

6.2 Treatment Planning (Arm 2)

Planning will follow current LRCP and VUmc practices treatment of lung, liver and brain lesions. Treatment can be delivered using static beams (either 3D-conformal radiotherapy or intensity-modulated) or rotational therapy (volumetric modulated arc therapy, or tomotherapy). Priority will be placed on generating clinically acceptable plans while minimizing complexity, planning time, and treatment time.

Dose constraints are listed in Tables 2-5 for 1-, 3-, 5-, and 8-fraction regimens.

It is strongly recommended that dose constraints not be exceeded. If a dose constraint cannot be achieved due to overlap of the target with an organ at risk, the fractionation can be increased or the target coverage compromised in order to meet the constraint. It is strongly recommended that in cases where the target coverage is compromised in order to meet the constraint, the mean dose delivered to the GTV should be at least 80% of the nominal dose in Tables 1. All such cases of dose reduction or target coverage compromise must be approved by the local PI prior to treatment. Any cases where dose constraints to normal tissues are exceeded must be approved by one of the PIs prior to treatment. For vertebral tumors, an adequate PRV of 2 mm must be added to the spinal cord, and the dose constraints apply to this PRV.

For lung tumors, doses are prescribed to approximately the 80% isodose line surrounding the PTV, resulting in a hotspot of 120-140%; the latter should fall within the GTV. 95% of the PTV should be covered by the prescription dose, and 99% of the PTV should be covered by 90% of the prescription dose.

For other tumor sites, doses are prescribed to approximately the 100% isodose level and 95% of the PTV should receive approximately 95% of the prescription dose. Doses should be corrected for tissue inhomogeneities. Several non-overlapping 6/10 MV beams (on the order of 7-11 beams) or 1-2 VMAT arcs combined possibly with a few non-coplanar beams should be utilized. Non-coplanar beams can be used to reduce 50% isodose volume for ungated treatments. Coplanar beams are recommended for respiratory-gated treatment.

The prescription points stipulated above are recommendations, and the prescription point may vary depending on the institution and the platform used. Prescriptions to the 60-90% isodose line are permitted in order to produce an optimal treatment plan. However, in all cases, the normal tissue dose constraints must be met.

For lung or liver metastases, each metastasis can be treated with a separate isocenter if metastases are well-separated. Since most metastases are treated every other day (table 1), when two metastases are treated, these can be done on alternating days to reduce the daily time required on the linear accelerator (e.g. Monday/Wed/Friday for one target, and Tues/Thurs/Mon for another). For brain metastases, all the metastases should be treated at the same time. For bone metastases, if multiple metastases can be imaged and localized at the same time, they can be treated at the same time, otherwise, they can be treated on alternate days.

The sequencing of tumor sites is at the discretion of individual physicians, but in general should begin with the brain, due to risks associated with progression, followed thereafter by liver, lung, and bone.

6.3 Quality Assurance (Arm 2)

In order to ensure patient safety and effective treatment delivery, a robust quality assurance protocol is incorporated. The following requirements must be completed for each patient:

- Prior to treatment, each patient must be discussed at quality assurance (QA) rounds.
- All radiotherapy plans must meet target dose levels for organs at risk (Tables 2-5).
 Prior to plan approval, the dose to each organ at risk must be verified by the physicist or treating physician. It is strongly recommended that dose constraints not be exceeded.
- All dose delivery for intensity-modulated plans (including arc-based treatments) will be confirmed before treatment by physics staff.
- Cone-beam CT will be used to verify patient positioning immediately prior to treatment. Ideally, direct tumour localization should be performed for stereotactic treatments of soft tissues. For gated SBRT treatments, direct tumour localization will be performed by matching the tumour position with the ROI defined by IGTV_CBCT. This will be followed by a gated 2D-kV in the AP plane to verify the gating window. In the absence of direct tumour localization, reliable soft tissue surrogates are recommended. A repeat CBCT will be done 25 minutes after the first, if delivery requires more than 25 minutes. A final CBCT may be done after completion of treatment.

6.3.1 Quality Assurance for Centres Joining Study

Prior to opening the study, each participating research centre will be required to send to one of the Principal Investigators a mock treatment plan for the anatomic sites that will be treated (e.g. Lung, brain, liver, adrenal), to ensure that the treatment plans are designed in compliance with the protocol. The principal investigators will provide pertinent CT datasets. Each participating research centre can choose which tumor sites will be treated at their individual centre (i.e. some centres may only choose to treat a subset of the eligible metastatic sites).

6.4 Chemotherapy

Patients treated with prior chemotherapy are eligible for this study, however, no chemotherapy agents (cytotoxic, or molecularly targeted agents) are allowed within the period of time commencing 4 weeks prior to radiotherapy (conventional or SABR)

lasting until 2 weeks after the last fraction. Hormonal therapy is allowed. Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine, adriamycin) are discouraged within the first month after SABR.

6.5 Further radiotherapy for progressive disease at new metastatic sites

Patients in Arm 1 who develop new, untreated metastatic deposits can receive palliative radiotherapy for any new such sites of progression.

Patients in Arm 2 who develop new, untreated metastatic deposits should be considered for SABR at those sites, if such deposits can be treated safely with SABR, and if the treating institution offers SABR for that body site. If SABR is not possible, then palliative RT can be delivered if indicated.

7.0 ADVERSE EVENTS

7.1 Definitions

Adverse Event (AE) or reaction is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may *not* be considered related to the medical treatment or procedure.

Serious Adverse Event (SAE) or reaction as defined in the ICH Guideline: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, E2A Section IIB includes any untoward medical occurrence that at any dose:

- Results in death
- Is life-threatening (refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.)
- Results in persistent or significant disability/incapacity
- Requires in-patient hospitalization or prolongation of existing hospitalization
- Is a congenital anomaly/birth defect

Important medical events that may not be immediately life-threatening or result in death or hospitalization may be considered a serious adverse event, when, based upon medical and scientific judgment, they may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above.

Unexpected adverse reaction is one that the nature and severity is not consistent with the applicable product information (e.g., Investigator's Brochure or Product Monograph, described in the REB/IRB approved research protocol or informed consent document), or occurs with more than expected frequency.

7.2 Causality (attribution)

An adverse event or reaction is considered **related** to the research intervention if there is a reasonable possibility that the reaction or event may have been caused by the research intervention (i.e. a causal relationship between the reaction and the research intervention cannot be ruled out by the investigator(s)).

The relationship of an AE to the study treatment (causality) will be described using the following definitions:

Unrelated: Any adverse event for which there is evidence that an alternative

etiology exists or for which no timely relationship exists to the administration of the study treatment and the adverse event does not follow any previously documented pattern. The adverse event, after careful consideration by the investigator, is clearly and incontrovertibly

due to causes other than the intervention.

Unlikely: Any adverse event for which the time relationship between the study

treatment and the event suggests that a causal relationship is unlikely and/or the event is more likely due to the subject's clinical condition or

other therapies concomitantly administered to the subject.

Possible: Any adverse event occurring in a timely manner after the

administration of the study treatment that follows a known pattern to the intervention and for which no other explanation is known. The adverse event, after careful consideration by the investigator, is considered to be

unlikely related but cannot be ruled out with certainty.

Probable: Any adverse event occurring in a timely manner after the administration of the study treatment that follows a known pattern to the

intervention and for which no other explanation is known. The adverse event, after careful consideration by the investigator, is believed with a

high degree of certainty to be related to the intervention.

Definitely Related: Any adverse event occurring within a timely manner after

administration of the study treatment that is a known sequela of the intervention and follows a previously documented pattern but for which no other explanation is known. The adverse event is believed by the investigator to be incontrovertibly related to the intervention.

7.3 Severity

The severity of adverse events will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grading scale (see (http://ctep.cancer.gov). [Appendix 5]

Grade 1: Mild
Grade 2: Moderate
Grade 3: Severe

Grade 3: Severe
Grade 4: Life-threatening or disabling

Grade 5: Death

<u>Note</u>: The term "severe" is a measure of intensity: thus a severe adverse event is not necessarily **serious**. For example, nausea of several hours' duration may be rated as severe, but may not be clinically serious.

7.4 <u>Immediately Reportable Adverse Events</u>

Any grade 4 or 5 adverse reaction that is definitely, probably, or possibly the result of protocol treatment must be verbally reported to the Principal Investigator and Co-Investigators within 24 hours of discovery, and to the approving research ethics board (REB) as per their reporting guidelines.

Local and non-local SAEs will be reported to the applicable REB as per their reporting guidelines. All **serious**, **unexpected** adverse events or reactions **regardless of causality** will be reported within **7** days of discovery to the pertinent REB.

NOTE: include conditions that are <u>NOT</u> considered a SAE in this protocol, e.g., hospitalizations for routine procedures, disease progression.

The Principal Investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies).

8.0 SUBJECT DISCONTINUATION / WITHDRAWAL

Subjects may voluntarily discontinue participation in the study at any time. If a subject is removed from the study, the clinical and laboratory evaluations that would have been performed at the end of the study should be obtained. If a subject is removed because of an adverse event, they should remain under medical observation as long as deemed appropriate by the treating physician.

9.0 FOLLOW-UP EVALUATION AND ASSESSMENT OF EFFICACY

Patients will be seen every three months post-randomization for the first two years, and every six months until 5 years after treatment. At each visit, a history and physical examination will be conducted by the oncologist, and CTC-AE toxicities recorded. The FACT-G Quality of life questionnaire is to be completed at each visit. (Appendix 4) After 1st progression, status and quality of life to be completed as per Appendix 2.

CT head, chest, abdomen and pelvis, and bone scans will be repeated at 3 and 6 months, then every six months. Patients randomized to Arm 2 will be considered SABR for salvage if new sites of disease develop. Additional Imaging or laboratory investigations should be carried out at the discretion of the oncologist, based on findings in the history or physical, and additional treatment (e.g. further chemotherapy) is at the discretion of the oncologists. For patient's in Arm 1 and 2 after 1st progression further CTs and bone scans are at the discretion of treating oncologist.

For patients who reach the 5-year follow-up visit, they will be re-consented to undergo additional annual follow-up until a total of 10-years post-randomization. This will consist of annual visits that include history and physical, QOL scoring, and toxicity score. Other investigations beyond 5 years, including imaging, are at the discretion of the treating physicians.

9.1 Measurement of Response

9.1.1. Survival outcomes: Overall survival will be measured as time until death from any cause, and progression-free survival as time to either progression or death, whichever occurs first.

9.1.2. Lesion control rate

Lesional response will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3): 205-216, 2000] See http://ctep.info.nih.gov/guidelines/recist.html for further details.

The sum of the longest diameter (LD) for all target lesions will be calculated and reported as the baseline sum LD. The baseline sum LD will be used as reference by which to characterize the objective tumor response.

Response Criteria: Evaluation of target lesions

*Complete Response Disappear

(CR):

Disappearance of all target lesions

*Partial Response (PR): At least a 30% decrease in the sum of the LD of

target lesions, taking as reference the baseline sum

LD

*Progressive Disease

(PD):

At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum

LD recorded since the treatment started or the

appearance of one or more new lesions

*Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor

sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment

started

9.2 Assessment of Safety

Safety will be assessed by the data safety and monitoring committee (DSMC), see Section 10). Adverse events (refer to section 7-9 for recording and reporting)

10.0 STATISTICS AND SAMPLE SIZE CALCULATION

10.1 Endpoints

Primary Endpoint:

- Overall Survival
 - Defined as time from randomization to death from any cause

Secondary endpoints:

- Quality of life
 - Assessed with the Functional Assessment of Cancer Therapy: General (FACT-G)
- Toxicity
 - Assessed by the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4
- Progression-free survival
 - Time from randomization to disease progression at any site or death
- Number of cycles of further chemotherapy or systemic therapy

10.2 Stratification

This sample size allows for one stratification factor at randomization, which will be number of metastatic sites (1-3 vs. 4-5).

10.3 Sample Size

This study will employ a randomized phase II screening design, to conduct a preliminary and non-definitive randomized comparison between the control and experimental arms. The study will aim to detect a signal in improved overall survival that would be used to design a phase III study to definitely compare survival outcomes between the two groups. The study will therefore be designed with alpha=0.20 and beta=0.20 (as recommended for phase II randomized screening studies²³). It is estimated that the median survival of the control group after randomization in this study will be 9 months.

There will be a 1:2 randomization between Arm 1 and Arm 2. In order to detect a 6-month improvement in median survival from 9 months to 15 months with SABR, a total of 93 patients (31 in Arm 1 and 62 in Arm 2) will be needed. Assuming a 5% rate of loss to follow-up, a total of 99 patients will be accrued (33 in Arm 1 and 66 in Arm 2). The study projects accrual over 48 months with 12 months of additional follow-up. Accrual targets are as follows: 20 patients in year 1, and 25-30 patients in years 2, 3, and 4.

10.4 Analysis Plan

Patients will be analyzed in the groups to which they are assigned (intention-to-treat).

Primary Endpoint

Survival will be calculated using the Kaplan-Meier method with differences compared using the stratified log-rank test. Pre-planned subgroup analysis will occur based on stratification variables. A Cox multivariable regression analysis will be used to determine baseline factors predictive of survival.

Secondary Endpoints

Quality of life at 6 months will be measured using FACT-G scores, with differences between groups tested using the Student's t-test. Differences in rates of grade 2 or higher toxicity between groups will be tested using the Fisher's Exact Test. Differences in progression free survival will be tested using the stratified log-rank test. Differences in the number of cycles of further chemotherapy/systemic therapy will be tested using the Student's t-test.

10.5 Data Safety Monitoring Committee

The DSMC will meet annually after study initiation to review toxicity outcomes. If any grade 3-5 toxicity is reported, the DSMC will review the case notes to determine if such toxicity is related to treatment. If the DSMC deems that toxicity rates are excessive (>25% grade 3 toxicity, or >5% grade 4 or 5 toxicity), then the DSMC can, at its discretion, recommend cessation of the trial, dose adjustment, or exclusion of certain treatment sites that are deemed as high-risk for complications.

Interim analysis: the DSMC will conduct one interim analysis once 50 patients are accrued. For this analysis, the DSMC will be blinded to the identity of each treatment arm, but OS data will be presented for each arm. The DSMC will recommend stopping the trial if there is an OS difference that is statistically significant with a threshold of p<0.001 using the log-rank test. Furthermore, if the median OS among all patients is substantially different than estimated in the sample size calculation, the DSMC can recommend increasing or decreasing the target accrual in order to maintain statistical power.

11.0 ETHICAL CONSIDERATIONS

The Principal Investigator will obtain ethical approval and clinical trial authorization by competent authorities according to local laws and regulations.

11.1 Institutional Review Board (IRB) / Research Ethics Board (REB)

The protocol (and any amendments), the informed consent form, and any other written information to be given to subjects will be reviewed and approved by a properly constituted Institutional Review Board (IRB)/Research Ethics Board (REB), operating in accordance with the current federal regulations (e.g., Canadian Food and Drug

Regulations (C.05.001); US Code of Federal Regulations (21CFR part 56)), ICH GCP and local regulatory requirements. A letter to the investigator documenting the date of the approval of the protocol and informed consent form will be obtained from the IRB/REB prior to initiating the study. Any institution opening this study will obtain REB IRB/REB approval prior to local initiation.

11.2 Informed Consent

The written informed consent form (Appendix 3) is to be provided to potential study subjects should be approved by the IRB/REB and adhere to ICH GCP and the ethical principles that have their origin in the Declaration of Helsinki. The investigator is responsible for obtaining written informed consent from each subject, or if the subject is unable to provide informed consent, the subject's legally acceptable representative, prior to beginning any study procedures and treatment(s). The investigator should inform the subject, or the subject's legally acceptable representative, of all aspects of the study, including the potential risks and benefits involved. The subject should be given ample time and opportunity to ask questions prior to deciding about participating in the study and be informed that participation in the study is voluntary and that they are completely free to refuse to enter the study or to withdraw from it at any time, for any reason.

The informed consent must be signed and dated by the subject, or the subject's legally acceptable representative, and by the person who conducted the informed consent discussion. A copy of the signed and dated written informed consent form should be given to the subject or the subject's legally acceptable representative. The process of obtaining informed consent should be documented in the patient source documents.

11.3 Confidentiality of Subject Records

The names and personal information of study participants will be held in strict confidence. All study records (CRFS, safety reports, correspondence, etc.) will only identify the subject by initials and the assigned study identification number. The investigator will maintain a confidential subject identification list (Master List) during the course of the study. Access to confidential information (i.e., source documents and patient records) is only permitted for direct subject management and for those involved in monitoring the conduct of the study (i.e., Sponsors, CRO's, representatives of the IRB/REB, and regulatory agencies). The subject's name will not be used in any public report of the study.

12.0 Authorship

Upon completion of this project, the results will be published in a peer-reviewed journal and presented at one or more conferences. Authorship on such publications will be decided by the two principal investigators in agreement, and will be commensurate with the relative accrual of each center and the amount of individual contribution, including study design, patient accrual, and data analysis.

14.0 Financial Support

This study is partially funded by grants from the Ontario Institute for Cancer Research through funding provided by the Government of Ontario and the London Regional Cancer Program. The granting agencies are not directly involved in data collection or analysis.

APPENDIX 1: ELIGIBILITY CHECKLIST

1.	Histologic diagnosis of cancer		(Yes / No)
2.	Appropriate re-staging within 12 weeks prior to randomizatio (see section 5.0)	n	(Yes / No)
3.	Age ≥ 18		(Yes / No)
4.	ECOG 0-1		(Yes / No)
5.	Patient available for subsequent follow-up appointments		(Yes / No)
6.	Anticipated survival > 6 months		(Yes / No)
7.	All sites of known disease amenable to treatment		(Yes / No)
8.	Underlying medical condition precluding adequate follow-up		(Yes / No)
9.	Prior RT or RFA to any site to be treated (Yes / No)		
10.	Concurrent chemotherapy, or molecularly targeted therapy (vito radiotherapy, concurrently, or two weeks after)	within 4	4 weeks prior (Yes / No)
11.	Primary disease controlled (see section 4.1)		(Yes / No)
12.	Lung lesions: 3 or fewer, maximum size 5 cm each	(Yes	/ No/NA)
13.	Liver lesions: 3 or fewer, maximum size 5 cm each	(Yes	No/NA)
14.	Brain lesions: 3 or fewer, maximum size 3 cm each	(Yes	/ No/NA)
15.	Bone lesions: 3 or fewer, maximum size 5 cm each [Note 1: lesions up to 6 cm may be eligible, see section 4.1] [Note 2: femoral lesions ineligible]	(Yes	/ No/NA)
16. 17.	Adrenal lesions: maximum size 5 cm each Spinal cord compression or tumor within 3 mm of cord on MR	`	′ No/NA) (Yes / No)
18.	Brain lesion requiring urgent decompression		(Yes / No)
19.	Negative pregnancy test within 4 weeks prior to randomization childbearing age	on for v	women of (Yes / No)

20.	Patient presented at tumor board or radiotherapy quality assurance to randomization	rounds prior (Yes / No)

20.

APPENDIX 2 – FOLLOWUP SCHEDULE

	Before	Years 1-2		Years 3-5	Years 6-10		
	Treatment	Every 3 months	Month 3, 6, 12, 18 and 24	Every 6 months	Annually		
History and Physical	X	X		Χ	X		
Baseline staging	X						
investigations							
(see section 5.0)							
CT head, chest,			X*	X			
abdomen, pelvis							
Bone Scan			X	X			
Toxicity Scoring		Χ		Χ	X♠		
FACT-G QOL scoring	X	X		Χ	X♠		

^{*}CT head is not required for cancers with low propensity of brain metastases (e.g. prostate)

- After 1st progression CTs and bone scans are to be completed at the discretion of the treating oncologist.
- •• After 1st progression patient status and quality of life are to be completed as per Appendix 2 Follow up schedule table. The quality of life may be done via mail or telephone call. ♠Patients who are unwilling or unable to travel for appointments may have toxicity, QOL ascertained by telephone.

APPENDIX 3

LETTER OF INFORMATION [TEMPLATE]

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial

<u>Introduction</u>

When cancer has spread from an original tumor to other sites of the body, it is classified as *metastatic*. Generally, for patients with metastatic cancer, the goal of treatment has been to slow down the cancer growth with chemotherapy and/or radiation, but treatments have been unable to get rid of the cancer altogether.

When there are only a few locations of metastatic cancer (called oligo-metastatic), some studies suggest that by removing or killing each of those cancer deposits, the cancer may be controlled for a long period of time. We are studying an approach to treat oligo-metastatic cancers with radiotherapy and you are being invited to participate. This new treatment is called stereotactic ablative radiotherapy (SABR).

SABR is a new radiation treatment that delivers high-dose, precise radiation to small tumors in 1-3 weeks of treatment. This new technique can potentially allow radiation treatments to be focused more precisely, and delivered more accurately than with older treatments. This improvement could help by reducing side effects and by improving the chance of controlling the cancer by more precisely treating the cancer. The purpose of this study is to compare SABR with current approaches of chemotherapy and conventional radiotherapy.

Description of Procedures

To compare SABR with conventional treatments, some patients in this study will be treated with SABR, and the others will receive standard treatments (chemotherapy and/or lower dose radiation, after discussion with your doctors). If you enter this study, you will randomly (by chance) be assigned to one of two groups: the SABR group or the standard group. Two-thirds of patients will be allocated to the SABR group and one-third to the standard group. Neither you nor your oncologist can choose which group you are allocated to.

If you are assigned to the 'standard' treatment group, immediate treatment can include chemotherapy and/or standard radiation therapy, and you will discuss this further with your oncologists.

If you are assigned to the 'SABR' group, you will undergo radiation treatments to all sites of metastases. The radiation planning process may involve construction of a plastic mask or special bean-bag to hold your head or body still for treatment followed by a CT scan. The information from the CT scan will be used to target the tumor and minimize the dose to normal tissues.

Treatments will be given either daily or every other day, on weekdays, over 1-3 weeks, depending on the location of your metastases. A CT scan through the region being treated will be taken on the radiation unit prior to treatment each day and your position for the treatment adjusted if necessary. Once your positioning is confirmed, the treatment will be given.

You will be followed regularly by your cancer specialist before and after treatment. The benefit of the treatment and any side effects will be measured. You will also have follow-up scans to assess the effects of treatment and look for new locations of metastasis. As part of the study, you will be asked to fill out questionnaires before and after treatment. These questionnaires can be expected to take 5-10 minutes to complete on each occasion.

Potential Benefits of Participating in the Study

Potential benefits of participating in the study include the possible decrease of side effects or improving your chances of curing the cancer using SABR.

Risks and discomforts

Potential side effects from radiation depend on the area being treated:

- Radiation treatments to the head and neck area or brain may commonly cause headache, hair loss, mild sunburn of the skin, decreased hearing or irritation of the ears, dryness or irritation of the eyes and dry or sore mouth or throat or loss of taste during radiation treatments. Common delayed (more than 6 months after treatment) side effects from radiation treatments to the head and neck area may include persistent dry mouth (common) as well as changes in thinking or memory (rare and only if the brain is treated).
- Radiation treatments to the chest area may commonly cause dry cough, sore throat or difficulty swallowing as well as mild sunburn of the skin. Delayed (late, >6months post treatment) side effects from radiation treatments to the chest area may rarely cause new or persistent difficulties with swallowing; shortness of breath or cough.
- Radiation treatments to the abdomen or pelvic area commonly include diarrhea or cramping
 of the bowels, discomfort or frequency of urination and possibly nausea. Rarely, delayed (late,
 >6months post treatment) side effects from radiation treatments may occur including
 persistent cramping, diarrhea or bleeding from the bowel; frequency or discomfort with
 urination or bleeding from the bladder.
- Radiation treatments to bone can be associated with increased pain, redness of the skin, and a risk of a broken bone.
- Fatigue during and following radiation treatments to any of these areas is common
- Radiation treatments are associated with a small risk of serious injury to tissues or organs that
 are included in the area being treated. This injury may show up months to years post
 treatment. In very rare instances, these side effects may result in death. Some of these side
 effects include (depending on whether these areas are being treated):
 - Brain injury resulting in loss of strength, sensation or thinking ability
 - Spinal cord injury resulting in paraplegia
 - Lung injury resulting in shortness of breath
 - Esophagus injury resulting in difficulty swallowing
 - Heart injury resulting in a heart attack or fluid collection on the heart
 - Bone injury resulting in a broken bone
 - Rectal or bowel injury resulting in bleeding or perforation (hole) or fistula (abnormal connection between the bowel and another organ)

- Bladder injury resulting in bleeding or perforation (hole) or fistula (abnormal connection between the bowel and another organ)
- Your physician will monitor your therapy and make adjustments to your treatment or prescribe
 medicines in order to manage side effects that occur during treatment. The radiation
 technique, daily dose and total dose of radiation for your treatment will be prescribed by your
 physician in order to minimize the chance of late serious injury as outlined above.

The potential side effects from SABR include those side effects associated with radiation treatments as listed above. It is also possible that SABR may be associated with unusually severe or unexpected side effects compared to radiation treatments using conventional radiation machines and techniques.

Withdrawal from the study

Participation in this study is voluntary. You may withdraw from the study at any time and still continue under the care of your radiation oncologist.

Privacy and Confidentiality:

All data that will be collected from this study will be considered confidential. We will maintain your confidentiality by using a unique identifier number on all documents instead of your name. A separate secure document will contain the linkage between your name and identifier number in order to minimize the possibility of a breach of you privacy. Your research records will be stored in a locked cabinet at the clinical trials unit. Once the data has been put into the research database, any identifying information will be removed from the database in order to protect your confidentially. If the results of the study are published, your name will not be used and no information that discloses your identity will be released or published without your explicit consent. By signing this consent form; you hereby consent to participation in this study. By consenting to this study you agree to allow us to confidentially collect this data. If you do not consent to this data collection, then you cannot participate in this study. Representatives of your local Research Ethics Board and the research team at your hospital may contact you or require access to your study-related records to monitor the conduct of the research.

If, during the course of this study, new information becomes available that may relate to your willingness to continue to participate, this information will be provided to you by the investigator.

Patient Rights:

Your participation in this study is voluntary. You may refuse to participate, refuse to answer any questions, or you may withdraw from the study at any time with no effect on your future care. If you decide not to participate or if you withdraw from the study before it is completed, the alternative procedures or courses of action will be explained to you by your doctor. A Data Safety Monitoring Committee will be reviewing the data from this research on a regular basis throughout the study. This will ensure that the participants are not exposed to increased risks as part of the study. If you are already participating in another study at this time, please inform the study doctor right away to determine if it is appropriate for you to participate in this study. We will tell you about new information that may affect your health, welfare, or willingness to stay in this study. If the results of the study are published, your name will not be used. If you would like to receive a copy of the overall results of this study, please put your name and address on a blank piece of paper and give it to the Clinical Research Associate.

If you have any questions about your rights as a research participant or the conduct of the study you may contact VP Research, Chief Administrator Officer, Lawson Health Research Institute, 519-667-6649.

Compensation and Costs:

There is no compensation to you in relation to this research study. A copy of this letter is for you to keep. Taking part in the study may result in added costs to you (e.g. parking, travel to the cancer clinic, etc.). In the event you are injured as a consequence of participation in this study due to the administration of the study treatment and/or procedure(s), your medical condition will be evaluated and medical care will be provided by one of the investigators or you will be referred for appropriate treatment. Although no funds have been set aside to compensate you in the event of injury or illness related to the study treatment or procedures, you do no waive any or your legal rights for compensation by signing the consent form.

CONSENT FORM

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial

I have read the accompanying letter of information and have had the nature of the study explained to me and I agree to participate. All questions have been answered to my satisfaction. Upon signing this form I will receive a copy.

Date

Patient's Signature

I certify that I have explained to the individual the nature and purpose, the potential benefits and possible risks associated with participation in this research study, have answered any questions that have been raised and have witnessed the above signature.

Date	Investigator's Signature

APPENDIX 4 – FACT-G Quality of Life Form

Below is a list of statements that other people with your illness have said are important. Please circle or mark one number per line to indicate your response as it applies to the <u>past 7 days</u>.

	PHYSICAL WELL-BEING	Not at all	A little bit	Some- what	Quite a bit	Very much
GP1	I have a lack of energy	0	1	2	3	4
GP2	I have nausea	0	1	2	3	4
GP3	Because of my physical condition, I have trouble meeting the needs of my family	0	1	2	3	4
GP4	I have pain	0	1	2	3	4
GP5	I am bothered by side effects of treatment	0	1	2	3	4
GP6	I feel ill	0	1	2	3	4
GP7	I am forced to spend time in bed	0	1	2	3	4
	SOCIAL/FAMILY WELL-BEING	Not at all	A little bit	Some- what	Quite a bit	Very much
GS1	I feel close to my friends	0	1	2	3	4
GS2	I get emotional support from my family	0	1	2	3	4
GS3	I get support from my friends	0	1	2	3	4
GS4	My family has accepted my illness	0	1	2	3	4
GS5	I am satisfied with family communication about my illness	0	1	2	3	4
GS6	I feel close to my partner (or the person who is my main support)	0	1	2	3	4
Q1	Regardless of your current level of sexual activity, please answer the following question. If you prefer not to answer it, please mark this box and go to the next section.					
GS7	I am satisfied with my sex life	0	1	2	3	4

Please circle or mark one number per line to indicate your response as it applies to the $\underline{\text{past 7}}$ $\underline{\text{days}}$.

	EMOTIONAL WELL-BEING	Not at all	A little bit	Some- what	Quite a bit	Very much
GE1	I feel sad	0	1	2	3	4
GE2	I am satisfied with how I am coping with my illness	0	1	2	3	4
GE3	I am losing hope in the fight against my illness	0	1	2	3	4
GE4	I feel nervous	0	1	2	3	4
GE5	I worry about dying	0	1	2	3	4
GE6	I worry that my condition will get worse	0	1	2	3	4
	FUNCTIONAL WELL-BEING	Not at all	A little bit	Some- what	Quite a bit	Very much
GF1	FUNCTIONAL WELL-BEING I am able to work (include work at home)				~	•
GF1		at all	bit	what	a bit	much
	I am able to work (include work at home)	at all	bit 1	what	a bit	much 4
GF2	I am able to work (include work at home)	o o	bit 1 1	what 2 2	a bit33	much 4 4
GF2 GF3	I am able to work (include work at home) My work (include work at home) is fulfilling I am able to enjoy life	0 0 0	bit 1 1 1	what222	3 3 3	4 4 4
GF2 GF3 GF4	I am able to work (include work at home) My work (include work at home) is fulfilling I am able to enjoy life I have accepted my illness	0 0 0 0	bit 1 1 1 1	what 2 2 2 2	3 3 3 3	4 4 4 4

<u>APPENDIX 4 – Common Terminology Criteria for Adverse Events (CTC-AE) Scoring version 4.0</u>

Available at:

http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40

References

- 1. Hellman S, Weichselbaum R: Oligometastases. Journal of Clinical Oncology 13:8-10, 1995
- 2. Macdermed DM, Weichselbaum RR, Salama JK: A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol 98:202-6, 2008
- 3. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 113:37-49, 1997
- 4. Rusthoven KE, Kavanagh BD, Burri SH, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. Journal of clinical oncology 27:1579-84, 2009
- 5. Rusthoven KE, Kavanagh BD, Cardenes H, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. Journal of clinical oncology 27:1572-8, 2009
- 6. Louie AV, Rodrigues G, Yaremko B, et al: Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer. Clin Lung Cancer 10:174-9, 2009
- 7. Milano MT, Katz AW, Schell MC, et al: Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 72:1516-22, 2008
- 8. Inoue T, Katoh N, Aoyama H, et al: Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions. Jpn J Clin Oncol 40:788-94, 2010
- 9. Milano MT, Philip A, Okunieff P: Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int J Radiat Oncol Biol Phys 73:832-7, 2009
- 10. Treasure T, Fallowfield L, Farewell V, et al: Pulmonary metastasectomy in colorectal cancer: Time for a trial. European Journal of Surgical Oncology (EJSO) 35:686-689, 2009
- 11. Primrose J, Treasure T, Fiorentino F: Lung metastasectomy in colorectal cancer: is this surgery effective in prolonging life? Respirology 15:742-6, 2010
- 12. Inoue T, Katoh N, Aoyama H, et al: Clinical Outcomes of Stereotactic Brain and/or Body Radiotherapy for Patients with Oligometastatic Lesions. Japanese Journal of Clinical Oncology 40:788-794, 2010
- 13. Andrews DW, Scott CB, Sperduto PW, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain

metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665-72, 2004

- 14. Treasure T, Fallowfield L, Lees B: Pulmonary Metastasectomy in Colorectal Cancer: The PulMiCC Trial. Journal of Thoracic Oncology 5:S203-S206 10.1097/JTO.0b013e3181dca239, 2010
- 15. Rodrigues G, Videtic GMM, Sur R, et al: Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. 1:60-71, 2011
- 16. Lutz S, Berk L, Chang E, et al: Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based Guideline. International Journal of Radiation Oncology*Biology*Physics 79:965-976, 2011
- 17. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, et al: Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat.Oncol. 4:1, 2009
- 18. Lock M, Gaede S, Sinclair K, et al: Phase I Study of Image-Guided and Radiobiologically-Guided Stereotactic Body Radiotherapy for Hepatic Lesions, Canadian Association of Radiation Oncologists Annual Meeting Abstract 38, 2010
- 19. Lagerwaard FJ, van der Hoorn EAP, Verbakel WFAR, et al: Whole-Brain Radiotherapy With Simultaneous Integrated Boost to Multiple Brain Metastases Using Volumetric Modulated Arc Therapy. International Journal of Radiation Oncology*Biology*Physics 75:253-259, 2009
- 20. Rodrigues G, Yartsev S, Yaremko B, et al: Phase I Trial of Simultaneous In-Field Boost With Helical Tomotherapy for Patients With One to Three Brain Metastases. International Journal of Radiation Oncology*Biology*Physics In Press, Corrected Proof
- 21. Kuijper IT, Dahele M, Senan S, et al: Volumetric modulated arc therapy versus conventional intensity modulated radiation therapy for stereotactic spine radiotherapy: A planning study and early clinical data. Radiotherapy and Oncology 94:224-228, 2010
- 22. Timmerman RD: An Overview of Hypofractionation and Introduction to This Issue of Seminars in Radiation Oncology. Seminars in Radiation Oncology 18:215-222, 2008
- 23. Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. Journal of clinical oncology 23:7199-206, 2005